Physician profile
Tabassum Hatimi
NPI 1881652022
$5,270.57
in general payments reported to CMS, 2019-2025
38 companies · $1,259 in 2025
The $1,259 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $877 · 2020: $160 · 2022: $821 · 2023: $1,073 · 2024: $1,080 · 2025: $1,259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,412 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,411.91 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $910.18 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $707.47 | 2022-2025 | |
| Lilly USA, LLC | $537.78 | 2019-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $463.10 | 2022-2025 | |
| Pfizer INC. | $442.62 | 2019-2025 | |
| Genzyme Corporation | $240.00 | 2019-2020 | |
| Lundbeck LLC | $186.66 | 2023-2025 | Rexulti |
| Amgen INC. | $179.07 | 2019-2025 | Evenity, Otezla, Repatha |
| Axsome Therapeutics, INC. | $145.56 | 2024-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $135.87 | 2019-2025 | Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $113.42 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $110.85 | 2019-2023 | Xarelto |
| Shield Therapeutics INC | $103.46 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $98.73 | 2023-2025 | Rexulti |
| Medtronic, INC. | $93.05 | 2022-2025 | Intellis Adaptivestim |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabassum Hatimi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.